Coronary/Structural Heart

Teleflex to Introduce the New TrapLiner® Catheter in Europe and Showcase the Arrow® AC3 Optimus™ Intra-Aortic Balloon Pump (IABP) at the European Association for Percutaneous Cardiovascular Interventions Course (EuroPCR) 2018

WAYNE, Pa.–(BUSINESS WIRE)–Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies for critical care, urology and surgery, coronary and peripheral interventions, will showcase its complex PCI product portfolio and the Arrow® AC3 Optimus™ Intra-Aortic Balloon Pump (IABP) at the EuroPCR being held in Paris, France on May 22 – […]

Medtronic Begins U.S. Study of Drug-Eluting Stents to Evaluate Treatment of Bifurcation Lesions in Patients with Coronary Artery Disease

DUBLIN – May 16, 2018 – Medtronic plc (NYSE: MDT) today announced the initiation of a clinical study in the U.S. to assess the safety and efficacy of drug-eluting stents (DES) for the treatment of bifurcation lesions, which account for approximately 20 percent of all percutaneous coronary interventions (PCI).1 The Bifurcation Cohort, […]

Boston Scientific Announces Schedule of Presentations at EuroPCR 2018

MARLBOROUGH, Mass., May 16, 2018 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today announced the schedule of key presentations, including two late-breaking clinical trials, that will be featured at the annual EuroPCR Scientific Program, in Paris, on May 22-25. During the late-breaking sessions on Wednesday, May 23, data from the RESPOND trial will provide two-year, ‘real world’ […]

Pi-Cardia Initiates First-in-Human Study With Novel Non-Implant Based Treatment of Aortic Stenosis

REHOVOT, Israel, May 16, 2018 /PRNewswire/ –Pi-Cardia Ltd., announced today that it recently started its First-in-Human study with its Leaflex(TM) Performer catheter system. The Leaflex(TM) Performer is a trans-femoral catheter that uses two unique mechanical structures for scoring valve calcification at multiple locations, restoring leaflets flexibility and improving valve hemodynamics. […]

The FH Foundation® Begins Enrollment in PAGENT Study to Improve Understanding of Genetic Testing for Familial Hypercholesterolemia (FH)

PASADENA, Calif., May 16, 2018–  The FH Foundation, a leading research and advocacy organization, today announced the launch of a new research study that aims to understand the willingness for individuals with a clinical diagnosis of familial hypercholesterolemia (FH) and their family members to undergo confirmatory genetic testing, through a […]

RenalGuard Solutions Announces Appointment of Dr. Howard R. Levin as Chief Medical Officer

MILFORD, Mass.–(BUSINESS WIRE)–RenalGuard Solutions™, Inc., a medical device company focused on innovative technologies for the cardiac and vascular markets, today announced that Howard R. Levin, M.D., has been named the company’s chief medical officer. A veteran in the field of biomedical engineering and cardiology and one of the original developers […]

Ancora Heart Expands Enrollment of U.S. Early Feasibility Study for the AccuCinch System for Left Ventricular Repair

SANTA CLARA, Calif.–(BUSINESS WIRE)–Ancora Heart, Inc., a company developing a novel therapy to address heart failure, today announced the expansion of the company’s U.S. feasibility study to evaluate the investigational AccuCinch®Ventricular Repair System designed for the treatment of heart failure and functional mitral regurgitation (FMR). Ancora has received approval from […]

MyoKardia Doses First Patient in PIONEER Open-Label Extension Study of Mavacamten for Symptomatic, Obstructive Hypertrophic Cardiomyopathy

SOUTH SAN FRANCISCO, Calif., May 10, 2018 (GLOBE NEWSWIRE) — MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced the start of the PIONEER open-label extension (OLE) study of its investigational drug, mavacamten.  MyoKardia recently completed the Phase […]

Centers for Medicare and Medicaid Services Approves Reimbursement for BioCardia’s CardiAMP Cell Therapy in Pivotal Clinical Trial Studying Second Indication in Chronic Myocardial Ischemia

SAN CARLOS, Calif.–(BUSINESS WIRE)–BioCardia®, Inc., (OTC: BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced that the Centers for Medicare and Medicaid Services (CMS) has approved national reimbursement coverage for the CardiAMP Chronic Myocardial Ischemia Trial. “We are thankful for the CMS decision to […]

HighLife Appoints Dr. Martin Rothman as Independent Member of the Board

PARIS–(BUSINESS WIRE)–HighLife SAS, a medtech company focused on the development of a unique trans-catheter mitral valve replacement (TMVR) system to treat patients suffering from mitral regurgitation, announced today the appointment of Dr. Martin T. Rothman as non-executive independent member of its Board of Directors. Dr. Rothman retired recently from his position as Vice President of […]